Glucagon is not available over the counter in the United States. Every commercially available glucagon product, whether it comes as a traditional emergency kit, a nasal spray, or a prefilled auto-injector, requires a prescription from a licensed provider. That said, the landscape around glucagon access has been shifting in meaningful ways, with newer delivery devices, state-level pharmacy initiatives, and ongoing conversations about whether the prescription requirement itself should change.
Why Glucagon Still Requires a Prescription
Glucagon is a hormone that rapidly raises blood sugar by signaling the liver to release stored glucose. It is classified as an emergency medication for severe hypoglycemia, the kind of dangerously low blood sugar that can leave a person unconscious or unable to swallow anything by mouth.1PubMed. Glucagon: Its evolving role in the management of hypoglycemia The FDA categorizes it as a prescription drug because dosing, storage, and the clinical decision to administer it carry enough complexity that regulators have kept it behind a prescriber’s oversight.
That reasoning has drawn criticism. Advocates for broader access point out that naloxone, another emergency rescue medication, was reclassified as over-the-counter in 2023 after decades as prescription-only. The arguments are similar: the medication is used in a crisis, delay can be fatal, and the person who needs it is often unable to self-administer. Despite those parallels, the FDA has not taken the same step with glucagon, and no manufacturer has submitted a formal application for OTC status as of mid-2025.
State-Level Workarounds
Even without OTC status, several states have created pathways that let pharmacists dispense glucagon without a patient-specific prescription. These programs typically work through standing orders or collaborative practice agreements, where a physician or health authority writes a blanket protocol that allows any pharmacist in the state to assess a patient’s need and hand over glucagon on the spot. The details vary by state: some limit dispensing to people who can show they use insulin, while others are broader.
Community pharmacies are well-positioned to fill this gap. Research has found that pharmacy teams can identify people at high risk for severe hypoglycemia and improve access to glucagon, yet prescriptions remain remarkably rare. Glucagon prescriptions were filled by only about 8% of people using short-acting insulin, roughly 2% of those on long-acting insulin, and less than 1% of people with diabetes who were not using insulin at all.2JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. Ensuring glucagon access for people with diabetes: A case example from community pharmacy Those numbers reveal a striking disconnect between how many people could benefit from having glucagon on hand and how many actually do.
The Prescription Gap Is Enormous
The underfilling problem extends beyond routine prescribing. Even after a person with diabetes visits the emergency department for a hypoglycemic episode, the vast majority leave without picking up glucagon. One study found that fewer than 11% of people with type 1 diabetes and about 4% of people with type 2 diabetes filled a glucagon prescription after an ER visit for hypoglycemia.3Endocrine Practice. Glucagon Prescriptions for Diabetes Patients after Emergency Department Visits for Hypoglycemia A separate analysis of patients newly started on insulin confirmed the pattern: the majority never filled a glucagon prescription at all. Younger, healthier people with type 1 diabetes were somewhat more likely to have glucagon, as were younger people with type 2 diabetes who had prior emergency visits for low blood sugar.4Endocrine Practice. Glucagon Prescription Patterns In Patients With Either Type 1 Or 2 Diabetes With Newly Prescribed Insulin
Several forces feed this gap. Providers may not think to prescribe glucagon during a routine visit, especially for people with type 2 diabetes who are perceived as lower risk. Patients may not understand why they need it if they have never experienced a severe low. And when a prescription does get written, sticker shock at the pharmacy counter can stop people from filling it.
What Glucagon Costs and Why It Matters
Cost has been one of the most persistent barriers. Older glucagon emergency kits, which require mixing a powder with a diluent before injection, were already expensive. The newer, more user-friendly products that came to market in the late 2010s and early 2020s often carried higher list prices. A study examining out-of-pocket spending trends from 2010 to 2020 documented the financial burden on patients over that decade.5PubMed Central. Trends in Out-of-Pocket Cost of Glucagon, 2010-2020 Even with insurance, copays for branded glucagon products can run into the hundreds of dollars, and uninsured pricing is substantially worse.
The frustrating part is that glucagon is a medication people hope they never need to use. Paying a significant sum for something that sits in a drawer until an emergency, and that may expire before that emergency ever happens, understandably discourages people from filling the prescription. Manufacturer assistance programs and pharmacy discount cards can bring the cost down, but navigating those programs adds another layer of effort.
How the Available Products Differ
The glucagon landscape has changed dramatically over the past several years. Understanding what is on the market helps explain why access conversations have intensified.
- Traditional emergency kits: These contain a vial of powdered glucagon and a separate syringe filled with a liquid diluent. The caregiver has to inject the diluent into the vial, swirl to dissolve the powder, draw the solution back into the syringe, and then inject it into the patient. Under the stress of watching someone have a seizure or lose consciousness, these multi-step kits are notoriously difficult to use correctly.
- Nasal glucagon (Baqsimi): A dry powder delivered as a single puff into one nostril. No injection, no mixing, no measuring. The 3-mg nasal dose was shown to be noninferior to intramuscular injection, successfully treating more than 98% of hypoglycemic events in both children and adults. Most people can administer it in under a minute, compared with one to four minutes for the injectable kits, which often resulted in patients not receiving the full intended dose.6PubMed. Intranasal Glucagon: A New Way to Treat Hypoglycemic Emergencies
- Prefilled auto-injectors (Gvoke HypoPen, Zegalogue): These use liquid-stable glucagon formulations that eliminate the mixing step. You uncap, press against the thigh, and the device delivers the dose automatically.
The shift toward simpler devices matters because the old emergency kits failed people at alarming rates. In a simulated rescue scenario, only about 31% of caregivers successfully administered the traditional kit, compared with 88% who managed the auto-injector. Average rescue time roughly doubled with the old kits.7PubMed Central. Human Factors Usability and Validation Studies of a Glucagon Autoinjector in a Simulated Severe Hypoglycemia Rescue Situation
Usability Under Pressure
The performance gap between old kits and newer devices becomes even starker when you look at how quickly caregivers can act. In a study comparing a ready-to-use auto-injector (dasiglucagon) against the traditional glucagon emergency kit, 94% of trained caregivers successfully administered the auto-injector within 15 minutes, compared with 56% for the kit. Within the first two minutes, 88% of trained caregivers completed the auto-injector dose versus 40% for the kit. For untrained bystanders, half managed the auto-injector within two minutes, while just 8% accomplished the same with the old kit.8Diabetes Technology & Therapeutics. A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia
These numbers have practical consequences. Severe hypoglycemia can cause seizures, brain injury, and death. Minutes matter, and the old kits were effectively too complicated for many people to use under real-world panic. The newer devices still require a prescription, but they dramatically lower the skill barrier for the person who actually has to use them. If you carry glucagon for someone else or keep it at home, making sure you have a nasal or auto-injector product rather than an old-style kit is one of the single most impactful things you can do.
What to Do If You Cannot Get a Prescription Quickly
If you use insulin and do not currently have a glucagon prescription, there are a few practical routes. First, ask your prescriber at your next visit. Many endocrinologists and primary care doctors simply forget to write the prescription unless you bring it up. Second, check whether your state allows pharmacists to dispense glucagon under a standing order. A quick call to your pharmacy can clarify this. Third, if cost is the issue, look into manufacturer patient assistance programs or generic alternatives. A generic version of the traditional injectable kit has been available, though the newer devices do not yet have generic equivalents.
For the immediate emergency when no glucagon is available, oral glucose gel, juice, or regular soda can help if the person is conscious enough to swallow safely. If they are not conscious, calling 911 is the only safe option. Paramedics carry both glucagon and intravenous dextrose.
How Paramedics Use Glucagon in the Field
Emergency medical services have long relied on glucagon as a first-line treatment for hypoglycemia encountered outside the hospital. A survey of ambulance services found that more than three-quarters used glucagon as their sole prehospital treatment for low blood sugar, with the rest using a combination of glucagon and intravenous glucose. Notably, when IV glucose was available, patients reached full orientation in a median of about 11 minutes, compared with roughly 28 minutes with glucagon alone.9PubMed Central. A comparison of glucagon and glucose in prehospital hypoglycaemia That difference matters: glucagon works by telling the liver to release its stored sugar, which takes time and depends on the liver actually having glycogen reserves. IV glucose, by contrast, puts sugar directly into the bloodstream.
Nasal glucagon is beginning to appear in EMS protocols as well. A prehospital study of intranasal glucagon across 44 patients found that about a third showed substantial improvement in mental status, with blood sugar rising from an average of roughly 34 mg/dL to 87 mg/dL. Another 30% showed slight improvement, while 38% did not improve.10PubMed. Prehospital Intranasal Glucagon for Hypoglycemia The mixed results likely reflect the variety of causes behind prehospital hypoglycemia. Patients who have been drinking heavily, who are malnourished, or whose liver glycogen stores are depleted will not respond as well to glucagon regardless of how it is delivered, because the liver has little glucose left to release.
Glucagon for Hypoglycemia After Weight-Loss Surgery
Glucagon’s role extends beyond the traditional diabetes emergency. People who have undergone bariatric surgery, particularly gastric bypass, sometimes develop a condition called post-bariatric hypoglycemia. Their rearranged digestive anatomy causes exaggerated insulin spikes after eating, which can drive blood sugar dangerously low. Treatment options for this condition are limited, and researchers have been exploring whether automated glucagon delivery could help.
In a randomized trial of a closed-loop system that detected falling blood sugar and delivered small doses of glucagon, clinically significant hypoglycemia occurred in 7 of 12 participants after they received a placebo but in none after receiving glucagon. No episodes of rebound high blood sugar above 180 mg/dL occurred.11The Journal of Clinical Endocrinology & Metabolism. A Randomized, Placebo-Controlled Double-Blind Trial of a Closed-Loop Glucagon System for Postbariatric Hypoglycemia A separate research team designed a prediction algorithm using continuous glucose monitor data to recommend mini-dose glucagon before blood sugar dropped too far.12PubMed Central. Design and Clinical Evaluation of a Novel Low-Glucose Prediction Algorithm with Mini-Dose Stable Glucagon Delivery in Post-Bariatric Hypoglycemia
These applications are still experimental, but they highlight an expanding view of glucagon as more than just a last-resort injection for people with diabetes. If automated low-dose delivery systems reach the market, the question of how patients access glucagon will get even more pressing, because the medication would shift from something you keep in a drawer for an emergency to something used regularly.
Why the OTC Debate Keeps Coming Back
The case for making glucagon available without a prescription rests on a few observations that are hard to argue with. The medication has a strong safety profile when used for hypoglycemia. The newer delivery devices are simple enough that untrained bystanders can use them. And the current prescription requirement clearly is not getting glucagon into the hands of the people who need it: the vast majority of insulin users do not have it, and even people who land in the ER for severe low blood sugar usually leave without filling a prescription.
The counterarguments tend to focus on the fact that glucagon is an injectable or intranasal hormone, not a pill you pop at home. There are concerns about people self-treating situations that actually require medical evaluation, about proper storage (some forms need refrigeration, others do not), and about the theoretical risk of someone using glucagon when they do not actually have hypoglycemia. Glucagon can cause nausea and vomiting, and in rare cases it can raise blood sugar too aggressively in people who are not actually low.
For now, the practical reality is that you need a prescription. But the trend is clearly toward easier access, whether through state pharmacy programs, cheaper generic options, or possibly an eventual OTC reclassification. If you or someone you live with uses insulin, having a current glucagon product at home and knowing how to use it is worth the conversation with your provider and the trip to the pharmacy, even if the system makes both of those steps harder than they should be.